19 results on '"Mosenzon, Ofri"'
Search Results
2. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58
3. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus
4. Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus
5. Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction
6. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction
7. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
8. Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease
9. Abstract 14726: Serial Assessment of Cardiac Biomarkers and Risk of Cardiovascular Death or Hospitalization for Heart Failure in DECLARE-TIMI 58
10. Abstract 10006: The Effect of Dapagliflozin on Hospital Admissions in Patients With Type 2 Diabetes: Post Hoc Analysis of the DECLARE-TIMI 58 Trial
11. Abstract 13182: Dapagliflozin and Changes in Metabolic Syndrome in Patients With Type 2 Diabetes: A DECLARE TIMI 58 Sub-Analysis
12. Abstract 9393: A Genetic Risk Score to Predict Peripheral Artery Disease and Acute Limb Ischemia in Patients With Cardiometabolic Disease
13. Response by Mann et al to Letter Regarding Article, “Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial”
14. Abstract 15581: Effect of Dapagliflozin on Atrial Fibrillation/Flutter in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial
15. Abstract 15670: Relationship Between Baseline Cardiac Biomarkers and Cardiovascular Death or Hospitalization for Heart Failure in DECLARE-TIMI 58
16. Abstract 13488: Effect of Dapagliflozin in Reducing Recurrent Myocardial Infarction of Different Infarct Types and Sizes: Insights From Declare-Timi 58
17. Abstract 10083: The Efficacy and Safety of Dapagliflozin in Women and Men With Type 2 Diabetes Mellitus: Insights From The DECLARE-TIMI 58 Trial
18. Abstract 14894: Performance of a Genome-Wide Polygenic Risk Score to Predict Coronary Events in Patients With Diabetes Without Prior Myocardial Infarction
19. Response to Letter Regarding Article, “Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial”
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.